Drug intelligence / Profile preview

Biotene

Development stage
Unknown
Lead developer
Laclede
Modality
Small Molecules, Recombinant Proteins and Enzymes
Administration
Oral, Topical
01

Overview

Biotene is a specialized line of oral care products designed to alleviate the symptoms of xerostomia, commonly known as dry mouth. Originally developed by Laclede and currently owned by GSK, Biotene products are formulated to provide immediate and long-lasting relief for patients whose salivary production is compromised by conditions such as Sjögren's syndrome, diabetes, or as a side effect of medications and radiation therapy. The therapeutic efficacy of Biotene stems from its ability to supplement the mouth's natural defenses. Historically, the formulation was centered around the LP3 Enzyme System, which incorporates lactoperoxidase, lysozyme, and glucose oxidase to replicate the antimicrobial environment of healthy saliva. Modern iterations focus heavily on advanced humectants and lubricants, including glycerin, xylitol, and sorbitol, which help to hydrate oral tissues, balance pH, and prevent the complications associated with dry mouth, such as dental caries and oral infections.

Brand names
Biotene
Other names
Biotene OralbalanceBiotene Dry Mouth Oral RinseBiotene Moisturizing Gel
02

Targets

PGN (Peptidoglycan)

Beyond the preview

Go deeper on Biotene.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Biotene.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call